Citations

Showing 10 of 108152 citations.

Summary for Clinicians: Microbiological Laboratory Testing in the Diagnosis of Fungal Infections in Pulmonary and Critical Care Practice
Hage, Chadi A. , Carmona, Eva M. , Evans, Scott E. , Ruminjo, Joseph K., Thomson, Carey C. , Carmona, Eva M , Limper, Andrew H.

Mayo Clinic

Annals of the American Thoracic Society | September 17, 2019 | Volume: 16 | Issue: 12 | Pages: 1473-1477

10.1513/annalsats.201908-582cme | PMID 31526275 Get It

Commentary: Parietooccipital Transventricular Approach for Thalamic Cavernous Malformation: 2-Dimensional Operative Video
Patra, Devi Prasad, Bendok, Bernard R. , Quiñones‐Hinojosa, Alfredo , Meyer, Fredric B. , Patra, Devi P. , Bendok, Bernard R

Mayo Clinic

Operative Neurosurgery | September 17, 2019 | Volume: 17 | Issue: 4 | Pages: E151-E152

10.1093/ons/opz224 | PMID 31529129 Get It

Catheter Ablation Compared With Drug Therapy for Atrial Fibrillation—Reply
Packer, Douglas L. , Lee, Kerry L. , Mark, Daniel B.

Mayo Clinic

JAMA | September 17, 2019 | Volume: 322 | Issue: 11 | Pages: 1106

10.1001/jama.2019.10688 | PMID 31529005 Get It

Faculty Opinions recommendation of Rational Design of 5-(4-(Isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine (VX-970, M6620): Optimization of Intra- and Intermolecular Polar Interactions of a New Ataxia Telangiect
Kaufmann, Scott H.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | September 17, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.735738721.793565222 Get It

Faculty Opinions recommendation of A HER2-Targeting Antibody-Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model.
Kaufmann, Scott H.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | September 17, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.733126683.793565225 Get It

Faculty Opinions recommendation of Phase I study of ATR inhibitor M6620 in combination with topotecan in patients with advanced solid tumors.
Kaufmann, Scott H.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | September 17, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.732320460.793565223 Get It

Intravenous Bone Marrow Mononuclear Cells for Acute Ischemic Stroke: Safety, Feasibility, and Effect Size from a Phase I Clinical Trial
Haque, Muhammad , Zhu, Hongjian , Rowan, Paul J. , Aisiku, Imoigele P. , Juneja, Harinder S., Alderman, Susan , Barreto, Andrew D. , Suárez, José I. , Bambhroliya, Arvind , Hasan, Khader M. , Kassam, Mallikarjuna Rao, Aronowski, Jaroslaw , Gee, Adrian P. , Cox, Charles S. , Grotta, James C. , Savitz, Sean I. , Vahidy, Farhaan S , Rahbar, Mohammad H. , Lee, Dean Anthony , Grotta, James C

Mayo Clinic

Stem Cells | September 17, 2019 | Volume: 37 | Issue: 11 | Pages: 1481-1491

10.1002/stem.3080 | PMID 31529663 Get It

AbstractCellular therapy is a promising investigational modality to enhance poststroke recovery. We conducted a single-arm, phase I clinical trial to determine the safety and feasibility of intravenous (IV) administration of autologous bone marrow mononuclear cells (MNCs) after acute ischemic stroke (AIS). Patients with moderate severity of AIS underwent bone marrow harvest followed by IV reinfusion of MNCs within 24–72 hours of onset. A target dose of 10 million cells per kilogram was chosen based on preclinical data. Patients were followed up daily during hospitalization and at 1, 3, 6, 12, and 24 months for incidence of adverse events using laboratory, clinical (12 months), and radiological (24 months) parameters. The trial was powered to detect severe adverse events (SAEs) with incidences of at least 10% and planned to enroll 30 patients. Primary outcomes were study-related SAEs and the proportion of patients successfully completing study intervention. A propensity score-based matched control group was used for the estimation of effect size (ES) for day-90 modified Rankin score (mRS). There were no study-related SAEs and, based on a futility analysis, enrolment was stopped after 25 patients. All patients successfully completed study intervention and most received the target dose. Secondary analysis estimated the ES to be a reduction of 1 point (95% confidence interval: 0.33–1.67) in median day-90 mRS for treated patients as compared with the matched control group. Bone marrow harvest and infusion of MNCs is safe and feasible in patients with AIS. The estimated ES is helpful in designing future randomized controlled trials. Stem Cells 2019;37:1481–1491
Probability of Bladder Augmentation, Diversion and Clean Intermittent Catheterization in Classic Bladder Exstrophy: A 36-Year, Multi-Institutional, Retrospective Cohort Study
Szymanski, Konrad M. , Fuchs, Molly , McLeod, Daryl J. , Strine, Andrew C., VanderBrink, Brian A. , Yerkes, Elizabeth B. , Gargollo, Patricio C. , Rosoklija, Ilina , Whittam, Benjamin M.

Mayo Clinic

Journal of Urology | September 17, 2019 | Volume: 202 | Issue: 6 | Pages: 1256-1262

10.1097/ju.0000000000000552 | PMID 31526259 Get It

Management of paediatric humeral shaft fractures and associated nerve palsy
O’Shaughnessy, Maureen , Parry, Joshua A. , Liu, H., Stans, Anthony A. , Milbrandt, Todd A. , Larson, A. Noelle

Mayo Clinic

Journal of Children's Orthopaedics | September 17, 2019 | Volume: 13 | Issue: 5 | Pages: 508-515

10.1302/1863-2548.13.190012 | PMID 31695818 Get It

Purpose The aim of this study is to review the management of all paediatric humerus diaphyseal fractures treated at a single institution over a 20-year period. Methods Retrospective review from between 1996 and 2016 identified 96 humerus shaft fractures in paediatric patients (0 to 17 years). After excluding those deceased from inciting trauma, pathological and perinatal fractures, 80 patients remained for analysis. Data collected included age, fracture type, displacement, nerve palsy, treatment, complications and time to union. Radiographs were reviewed at the time of injury and at latest follow-up. Results Of 80 paediatric humeral diaphyseal fractures, 65 (81%) were treated with immobilization. In all, 15 (19%) fractures were treated with surgical stabilization. Most common indications were fracture displacement, open fractures and to improve mobilization in patients with multiple injuries. Fractures were stabilized with a plate (eight), flexible nails (five), external fixation (one) and percutaneous pinning (one). The operative group, compared with the nonoperative group, was older, had more high-energy mechanisms, more open fractures and increased fracture displacement. All patients in the nonoperative and operative groups went on to union with minimal complications. A nerve palsy was present in five patients (6%)with three of the five involving the radial nerve (4%). All nerve palsies were observed and had full neurological recovery. Conclusion Over a 20-year period nonoperative management of paediatric humerus shaft fractures was successful in the majority of patients. Operative stabilization, when rarely indicated, had a low complication rate and improved radiographic alignment. All nerve injuries fully recovered without surgical intervention. Level of evidence IV
Rituximab Versus Cyclophosphamide for Central Nervous System Involvement of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
Krishna, R. Vijay , Giacomi, Federica De , Kalina, Peter , Baqir, Misbah , Krishna, Rachana, Krishna, Rachana, Kumar, Neeraj , Specks, Ulrich

Mayo Clinic

JCR: Journal of Clinical Rheumatology | September 17, 2019 | Volume: 27 | Issue: 2 | Pages: 64-72

10.1097/rhu.0000000000001169 | PMID 31567753 Get It

Objective To compare the effectiveness of rituximab (RTX) with cyclophosphamide (CYC) in patients who have central nervous system (CNS) involvement in antineutrophil cytoplasmic antibody–associated vasculitis (AAV). Methods A computer-assisted search was conducted to identify all adults who received a diagnosis of AAV with CNS involvement from January 1, 1997, through July 1, 2017, at our institution. Results Of the 17 patients identified, 11 had received RTX, and 6 had received CYC. Age at diagnosis of CNS involvement was similar in both groups. In the RTX group, 91% of the patients were women; in the CYC group, 33% were women (p = 0.03). At the time of CNS presentation, orbital involvement had occurred in 6 patients in the RTX group and in none of the patients in the CYC group. Initial remission of induction was achieved in all patients (100%) in the CYC group and in 10 patients (91%) in the RTX group. Two patients had no response to RTX: 1 patient when RTX was used for remission induction at the time of diagnosis and the second patient when RTX was used for remission induction after relapse. The median follow-up was 38 months (range, 9–127 months). Central nervous system relapse occurred in 4 patients in the RTX group and in 1 patient in the CYC group. Of the 4 patients in the RTX group with relapse, 3 had marked ocular involvement. Both nonresponder patients in the RTX group had ocular involvement. Conclusion Rituximab is as effective as CYC in remission induction in patients with CNS involvement in AAV.